Tests VERVE-201 for safety in adults with hard-to-treat high cholesterol
Tests VERVE-201, a gene-editing drug, for safety in adults with high cholesterol.
Plain-language title generated from the registry record
Registry title: Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia
Key facts
- Where
- Chicoutimi, Montreal, and Toronto, CanadaSee the 3 sites
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT06451770, who can take part
Where in Canada
- Clinical Study CenterChicoutimi, CanadaTaking people
- Clinical Study CenterMontreal, CanadaTaking people
- Clinical Study CenterToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Verve Therapeutics, Inc.
- Trial code
- NCT06451770EU 2025-522617-39-00
- Record updated
- 23 October 2026
- Original description
VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory Hyperlipidemia.Read full original descriptionShow less
A Phase 1b Single Ascending Dose Study to Evaluate the Safety of VERVE-201 in Patients With Refractory Hyperlipidemia
VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory Hyperlipidemia.
VERVE-201 uses base-editing technology designed to inactivate the expression of the ANGPTL3 gene in the liver and lower circulating low-density lipoprotein cholesterol (LDL-C) and triglycerides. This study is designed to determine the safety and pharmacodynamic profile of VERVE-201 in this patient population.
Inclusion: Refractory hypercholesterolemia; Refractory hypertriglyceridemia.
Exclusion: Current treatment with monoclonal antibody targeting ANGPTL3 or prior treatment within specified timeframe; Active or history of chronic liver disease; Clinically significant or abnormal laboratory values as defined by the protocol.